Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Currency in EUR	2026
Operating Income	220.47 Million
Income Before Tax	230.09 Million
Income Tax Expense	23.12 Million
Net Income	206.97 Million
Eps	3.22
Epsdiluted	2.83
Weighted Average Shs Out	64.34 Million
Weighted Average Shs Out Dil	68.32 Million
Depreciation And Amortization	4.57 Million
Interest Expense	14.17 Million
Ebit	244.27 Million
Interest Income	4.83 Million
Net Interest Income	-1.03 Million
Period	Q2
Ebitda	225.03 Million
Net Cash Provided By Operating Activities	N/A
Source	yahoo

Ascendis Pharma A/S Annual Reports (10-K)